Patents by Inventor Dorah Daily

Dorah Daily has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted Aryl-Indole Compounds and Their Kynurenine/Kynuramine-Like Metabolites As Therapeutic Agents
    Publication number: 20110319494
    Abstract: This invention is directed to substituted aryl compounds, which are linked to a substituted indole moiety by various linkers, and the kynurenine/kynuramine-like metabolites of these agents, their preparation and pharmaceutical compositions containing these compounds. This invention further is directed to the pharmaceutical use of the compounds for inhibiting GSK3? kinase and/or modulating N-methyl-D-aspartate (NMDA) channel activities for the treatment of neurodegenerative and other disorders.
    Type: Application
    Filed: August 3, 2011
    Publication date: December 29, 2011
    Applicant: Neurim Pharmaceuticals (1991) Ltd.
    Inventors: Tal Peleg-Shulman, Moshe Laudon, Dorah Daily
  • Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents
    Patent number: 8003702
    Abstract: This invention is directed to substituted aryl compounds, which are linked to a substituted indole moiety by various linkers, and the kynurenine/kynuramine-like metabolites of these agents, their preparation and pharmaceutical compositions containing these compounds. This invention further is directed to the pharmaceutical use of the compounds for inhibiting GSK3? kinase and/or modulating N-methyl-D-aspartate (NMDA) channel activities for the treatment of neurodegenerative and other disorders.
    Type: Grant
    Filed: November 3, 2009
    Date of Patent: August 23, 2011
    Assignee: Neurim Pharmaceuticals (1991) Ltd.
    Inventors: Tal Peleg-Shulman, Moshe Laudon, Dorah Daily
  • Substituted Aryl-Indole Compounds and Their Kynurenine/Kynuramine-Like Metabolites As Therapeutic Agents
    Publication number: 20100048663
    Abstract: This invention is directed to substituted aryl compounds, which are linked to a substituted indole moiety by various linkers, and the kynurenine/kynuramine-like metabolites of these agents, their preparation and pharmaceutical compositions containing these compounds. This invention further is directed to the pharmaceutical use of the compounds for inhibiting GSK3? kinase and/or modulating N-methyl-D-aspartate (NMDA) channel activities for the treatment of neurodegenerative and other disorders.
    Type: Application
    Filed: November 3, 2009
    Publication date: February 25, 2010
    Applicant: NEURIM PHARMACEUTICALS (1991) LTD.
    Inventors: Tal Peleg-Shulman, Moshe Laudon, Dorah Daily
  • Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents
    Patent number: 7622495
    Abstract: This invention is directed to substituted aryl compounds, which are linked to a substituted indole moiety by various linkers, and the kynurenine/kynuramine-like metabolites of these agents, their preparation and pharmaceutical compositions containing these compounds. This invention further is directed to the pharmaceutical use of the compounds for inhibiting GSK3? kinase and/or modulating N-methyl-D-aspartate (NMDA) channel activities for the treatment of neurodegenerative and other disorders.
    Type: Grant
    Filed: October 1, 2007
    Date of Patent: November 24, 2009
    Assignee: Neurim Pharmaceuticals (1991) Ltd.
    Inventors: Tal Peleg-Shulman, Moshe Laudon, Dorah Daily
  • Substituted Aryl-Indole Compounds and Their Kynurenine/Kynuramine-Like Metabolites As Therapeutic Agents
    Publication number: 20080132559
    Abstract: This invention is directed to substituted aryl compounds, which are linked to a substituted indole moiety by various linkers, and the kynurenine/kynuramine-like metabolites of these agents, their preparation and pharmaceutical compositions containing these compounds. This invention further is directed to the pharmaceutical use of the compounds for inhibiting GSK3? kinase and/or modulating N-methyl-D-aspartate (NMDA) channel activities for the treatment of neurodegenerative and other disorders.
    Type: Application
    Filed: October 1, 2007
    Publication date: June 5, 2008
    Applicant: NEURIM PHARMACEUTICALS (1991) LTD.
    Inventors: Tal Peleg-Shulman, Moshe Laudon, Dorah Daily